RhumbLine Advisers’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

RhumbLine Advisers’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,123	Closed	-$134K	–	3172
2021 Q1	$134K	Buy	5,123 +51	+1%	+$2.32K	﹤0.01%	2905
2020 Q4	$183K	Buy	5,072 +534	+12%	+$19.3K	﹤0.01%	2865
2020 Q3	$161K	Buy	4,538 +65	+1%	+$2.83K	﹤0.01%	2751
2020 Q2	$190K	Buy	4,473 +3,749	+518%	+$253K	﹤0.01%	2788
2020 Q1	$58K	Hold	724	–	–	﹤0.01%	2850
2019 Q4	$67K	Buy	724 +9	+1%	+$759	﹤0.01%	2905
2019 Q3	$54K	Buy	715 +8	+1%	+$614	﹤0.01%	2921
2019 Q2	$70K	Buy	+707	New	+$54.8K	﹤0.01%	2948

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

RhumbLine Advisers's EVFM Position: Q2 2021 in Review

RhumbLine Advisers sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 5,123 shares — an estimated $134K sold.

RhumbLine Advisers first reported a position in EVFM in Q2 2019 and held it in 8 quarters. The position peaked at $190K in Q2 2020. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

RhumbLine Advisers reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
RhumbLine Advisers sold 5,123 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $134K.
RhumbLine Advisers first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
RhumbLine Advisers's Evofem Biosciences, Inc. Common Stock position peaked at $190K in Q2 2020.
81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.